In light of a recent study comprising of 1591 patients, published in The Lancet, rimegepant was found to be safe and effective for preventive treatment of migraine.

Robert Croop and researchers assessed the safety and efficacy of rimegepant (a calcitonin gene-related peptide receptor antagonist) to be used as a preventive therapy for migraine in this phase 2/3, randomised, double-blind, placebo-controlled trial.

People with migraine for at least a 1-year were randomised to oral rimegepant 75 mg (373 patients) or placebo (374 patients) every second day for a period of 12 weeks. Change from observation phase in monthly average number of migraine days in the final 4 weeks i.e. weeks’ 9 to 12 was considered as the primary outcome. The efficacy analysis (695 patients) and safety analysis (741 patients) included a minimum of 1 dose of study medicine.

In comparison with placebo, the variation in the mean number of migraine days in a month in the weeks’ 9 to 12 was found to be greater in case of rimegepant. The average number of migraine days per month during this time has been shown in below table:

Also, 36% of patients in each treatment group described an adverse event of mild or moderate intensity. Seven patients with rimegepant and four with placebo withdrew from the study because of adverse event. No mortality reported.